Posted on 288
Global Coalition for Adaptive Research (LOS ANGELES, CA), Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA, SYDNEY, Australia), and Kintara Therapeutics, Inc. (NASDAQ: KTRA, SAN DIEGO, CA) The Global Coalition for Adaptive Research (GCAR) in collaboration with Kazia and Kintara, today announced the activation of Kazia’s
paxalisib and Kintara’s
VAL-083 in GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment). GBM AGILE is a revolutionary patient-centered, adaptive platform trial for registration that tests multiple therapies for patients with newly-diagnosed and recurrent glioblastoma (GBM) – the deadliest form of brain cancer.
Kazia’s
paxalisib and Kintara’s
VAL-083 are entering the GBM AGILE trial, which initially opened in July 2019 and has screened over 370 patients to date.